Collplant Financial Statements From 2010 to 2025

CLGN Stock  USD 2.45  0.24  10.86%   
Collplant Biotechnologies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Collplant Biotechnologies' valuation are provided below:
Gross Profit
1.2 M
Market Capitalization
31.2 M
Enterprise Value Revenue
9.4103
Revenue
2.5 M
Earnings Share
(1.21)
We have found one hundred twenty available fundamental signals for Collplant Biotechnologies, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Collplant Biotechnologies' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 23rd of July 2025, Market Cap is likely to grow to about 68.9 M. Also, Enterprise Value is likely to grow to about 59.3 M

Collplant Biotechnologies Total Revenue

489,250

Check Collplant Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collplant Biotechnologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 596.9 K, Interest Expense of 25.7 K or Selling General Administrative of 3.9 M, as well as many indicators such as Price To Sales Ratio of 88.24, Dividend Yield of 0.0 or PTB Ratio of 4.63. Collplant financial statements analysis is a perfect complement when working with Collplant Biotechnologies Valuation or Volatility modules.
  
Build AI portfolio with Collplant Stock
Check out the analysis of Collplant Biotechnologies Correlation against competitors.
To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.

Collplant Biotechnologies Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets17.4 M18.7 M14.6 M
Slightly volatile
Other Current Liabilities961.6 K1.3 M813.7 K
Slightly volatile
Total Current Liabilities2.4 MMM
Slightly volatile
Total Stockholder Equity13.1 M13.5 M11 M
Slightly volatile
Property Plant And Equipment Net3.3 M5.3 M2.7 M
Slightly volatile
Accounts Payable888.8 K870 K768.4 K
Slightly volatile
Cash9.6 M11.9 M8.1 M
Slightly volatile
Non Current Assets Total3.8 M5.5 M3.2 M
Slightly volatile
Other Assets0.860.9164.4 K
Slightly volatile
Cash And Short Term Investments12.2 M11.9 M10.1 M
Slightly volatile
Common Stock Shares Outstanding6.1 M11.5 MM
Slightly volatile
Other Current Assets290.8 K248 K419.6 K
Slightly volatile
Other Stockholder Equity76.8 M122.8 M65 M
Slightly volatile
Total Liabilities4.3 M5.2 M3.6 M
Slightly volatile
Total Current Assets13.6 M13.2 M11.3 M
Slightly volatile
Intangible Assets261.4 K131 K325.2 K
Slightly volatile
Common Stock2.6 MM2.2 M
Slightly volatile
Net Receivables333.5 K583 K417.4 K
Pretty Stable
Common Stock Total Equity3.5 M3.4 M1.8 M
Slightly volatile
Liabilities And Stockholders Equity18.4 M18.7 M15.3 M
Slightly volatile
Inventory637.4 K440 K474.4 K
Slightly volatile
Property Plant And Equipment Gross12.9 M12.3 M4.4 M
Slightly volatile
Net Tangible Assets54.2 M51.6 M17.8 M
Slightly volatile
Property Plant Equipment3.5 M6.5 M3.1 M
Slightly volatile
Non Current Liabilities Total2.8 M2.3 M1.9 M
Slightly volatile
Non Current Liabilities Other327.4 K283.2 K425.8 K
Slightly volatile
Short and Long Term Debt Total3.2 M3.1 M3.3 M
Pretty Stable
Net Invested Capital19.1 M13.5 M12.6 M
Slightly volatile
Net Working Capital16.4 M10.2 M10.7 M
Slightly volatile
Current Deferred Revenue27.4 K28.8 K624.4 K
Slightly volatile
Capital Stock4.1 MM2.7 M
Slightly volatile
Capital Lease Obligations2.6 M3.1 M3.4 M
Slightly volatile

Collplant Biotechnologies Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization596.9 KM519.1 K
Slightly volatile
Interest Expense25.7 K17 K22.1 K
Slightly volatile
Selling General Administrative3.9 M5.6 M3.3 M
Slightly volatile
Selling And Marketing Expenses38.7 K43.2 K49.6 K
Slightly volatile
Other Operating Expenses11.1 M17.8 M9.5 M
Slightly volatile
Research Development6.2 M10.5 M5.4 M
Slightly volatile
Total Operating Expenses10.1 M16.1 M8.7 M
Slightly volatile
Interest Income411.2 K738 K223.6 K
Slightly volatile
Reconciled Depreciation810 KM551 K
Slightly volatile

Collplant Biotechnologies Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.3 M1.7 M1.1 M
Slightly volatile
Begin Period Cash Flow28 M26.7 M8.7 M
Slightly volatile
Depreciation601.9 KM523.1 K
Slightly volatile
Capital Expenditures685.4 K483 K564.2 K
Slightly volatile
Total Cash From Financing Activities8.6 KK5.6 M
Very volatile
End Period Cash Flow9.7 M11.9 M8.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio88.2480.0681140
Slightly volatile
PTB Ratio4.633.06245.2204
Pretty Stable
Days Sales Outstanding6344132.1 K
Slightly volatile
Book Value Per Share1.121.17562.6489
Slightly volatile
Average Payables550.4 K985.4 K864.6 K
Slightly volatile
Stock Based Compensation To Revenue3.323.33796.4914
Slightly volatile
Capex To Depreciation0.870.46530.9903
Slightly volatile
PB Ratio4.633.06245.2204
Pretty Stable
EV To Sales72.7762.9263126
Slightly volatile
Inventory Turnover3.883.69321.8735
Slightly volatile
Days Of Inventory On Hand93.8998.8308580
Very volatile
Payables Turnover1.061.86780.9979
Slightly volatile
Sales General And Administrative To Revenue0.820.8717.2401
Slightly volatile
Average Inventory802.5 K764.3 K432.9 K
Slightly volatile
Research And Ddevelopement To Revenue15.3720.417530.3803
Slightly volatile
Capex To Revenue0.740.93791.2015
Pretty Stable
Cash Per Share0.991.03972.1915
Slightly volatile
Days Payables Outstanding186195K
Pretty Stable
Income Quality1.180.84851.3781
Pretty Stable
Intangibles To Total Assets0.00670.0070.051
Slightly volatile
Current Ratio4.34.43775.1911
Pretty Stable
Tangible Book Value Per Share1.111.16412.449
Slightly volatile
Receivables Turnover0.840.883410.7525
Slightly volatile
Shareholders Equity Per Share1.121.17562.6489
Slightly volatile
Debt To Equity0.220.22880.8446
Slightly volatile
Capex Per Share0.04010.04220.1206
Pretty Stable
Average Receivables372 K473.1 K452.5 K
Slightly volatile
Revenue Per Share0.04270.0450.3461
Slightly volatile
Interest Debt Per Share0.240.27050.2575
Slightly volatile
Debt To Assets0.210.16470.3046
Slightly volatile
Graham Number1.631.842.0054
Slightly volatile
Operating Cycle4865122.6 K
Slightly volatile
Price Book Value Ratio4.633.06245.2204
Pretty Stable
Days Of Payables Outstanding186195K
Pretty Stable
Ebt Per Ebit0.980.96281.1794
Pretty Stable
Company Equity Multiplier1.911.38951.6814
Pretty Stable
Long Term Debt To Capitalization0.0050.00530.2933
Slightly volatile
Total Debt To Capitalization0.260.18620.3917
Slightly volatile
Debt Equity Ratio0.220.22880.8446
Slightly volatile
Quick Ratio4.154.28965.0322
Pretty Stable
Net Income Per E B T0.930.891.0972
Pretty Stable
Cash Ratio3.164.00983.8353
Pretty Stable
Days Of Inventory Outstanding93.8998.8308580
Very volatile
Days Of Sales Outstanding6344132.1 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.861.03431.0637
Very volatile
Price To Book Ratio4.633.06245.2204
Pretty Stable
Fixed Asset Turnover0.09260.09750.6832
Slightly volatile
Debt Ratio0.210.16470.3046
Slightly volatile
Price Sales Ratio88.2480.0681140
Slightly volatile
Asset Turnover0.02610.02750.1375
Slightly volatile
Price Fair Value4.633.06245.2204
Pretty Stable

Collplant Biotechnologies Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap68.9 M65.5 M51.3 M
Slightly volatile
Enterprise Value59.3 M44.3 M45.5 M
Slightly volatile

Collplant Fundamental Market Drivers

Forward Price Earnings15.5521
Cash And Short Term Investments11.9 M

Collplant Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
22nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Collplant Biotechnologies Financial Statements

Collplant Biotechnologies investors utilize fundamental indicators, such as revenue or net income, to predict how Collplant Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue28.8 K27.4 K
Total Revenue515 K489.2 K
Cost Of Revenue1.6 M1.2 M
Stock Based Compensation To Revenue 3.34  3.32 
Sales General And Administrative To Revenue 0.87  0.82 
Research And Ddevelopement To Revenue 20.42  15.37 
Capex To Revenue 0.94  0.74 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(33.50)(35.17)

Pair Trading with Collplant Biotechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Moving against Collplant Stock

  0.4EC Ecopetrol SA ADRPairCorr
  0.37PFE Pfizer IncPairCorr
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Collplant Biotechnologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Collplant Biotechnologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Collplant Biotechnologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Collplant Biotechnologies Stock:
Check out the analysis of Collplant Biotechnologies Correlation against competitors.
To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.21)
Revenue Per Share
0.216
Quarterly Revenue Growth
19.969
Return On Assets
(0.38)
Return On Equity
(0.75)
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.